Promotion: Investments in small cap shares involves a high degree of risk and are not suitable for all investors. Companies listed on the AIM or Aquis market can be highly volatile and are considered high-risk speculative investments.
THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN MEDPAL PLC IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.
Further to its announcement on 1 October 2025 regarding the acquisition of key assets from Universal Pharmacy Limited (in administration) ("Universal"), Medpal (AIM:MPAL), is pleased to announce the opening of a distribution centre at Ecotech Business Park, Swaffham (the "Centre").
Included in the assets acquired by the Company's wholly owned subsidiary Medpal Limited from Universal was a Distance Selling Pharmacy (DSP) licence enabling nationwide distribution of medication and a warehouse unit at the Centre. The UK pharmacy regulator, the General Pharmaceutical Council ("GPhC"), ceased issuing new DSP licences in June 2025. Using some of the proceeds of the placing and retail offer also announced on 1 October 2025, Medpal Limited has acquired advanced robotic dispensing equipment and leased two adjacent units, tripling the size of the original facility to create a state-of-the-art, 24/7 automated medicines fulfilment hub, which will be integrated with AI to enable the delivery of over 100,000 prescriptions per month.
Access to the pharmacy service will be advertised nationally and via the Company's MedPal app. At any time of day or night, users of the service will be able to complete an AI-supported consultation, which will produce a recommendation for a prescription, which will be signed off by a qualified Independent Prescriber ("IP") or General Practitioner ("GP") and then fulfilled at the Centre, which, being entirely automated, operates 24 hours a day. Medication will then be delivered to the user either the same or next day. There will be no charge to the user for the consultation or prescription, only for the medication.
Highlights
· Tripled footprint at Ecotech Business Park to support national scale, resilience and extended hours.
· Automation-led operations: installation of an Omnicell VBM and a BD Rowa VMAX advanced robotic dispensing system to increase throughput, accuracy and cost efficiency.
· AI-enabled triage: MedPal Limited's AI triage routes users to appropriate care, with instant access to independent prescribers and GPs, providing oversight and issuing prescriptions where clinically appropriate.
· Faster access to treatment: launch of same-day and next-day delivery services for eligible prescription medicines, including weight-loss treatments and other therapies, subject to prescription and clinical suitability.
· 24/7 capability: continuous intake, verification and automated dispensing to improve service levels for both private and NHS prescriptions.
Revolutionising Primary Care Through AI and Robotics
The Centre brings together MedPal's "digital front door" (including the MedPal app) and advanced robotic dispensing, delivering a vertically integrated, low-cost, high-reliability fulfilment model.
The expanded facility is designed to:
· increase access to primary-care pathways by providing rapid digital assessment and streamlined prescribing;
· lower unit costs through automation, enabling competitive pricing and improved patient affordability;
· enhance safety and quality via barcoded workflows, machine vision checks and pharmacist oversight; and
· support growth in both direct-to-consumer private prescriptions and NHS prescription supply for community patients.
The Centre will initially focus on high-demand services including weight loss medications, and chronic disease management prescriptions with same-day delivery capability in key metropolitan areas and next-day delivery nationwide. The 24/7 operational model addresses the growing demand for telehealth services, particularly among working-age patients unable to access traditional GP surgeries during business hours.
At the heart of this development is the integration of MedPal's proprietary AI triage system with state-of-the-art robotic dispensing technology, which leverages AI and robotics to reduce dispensing errors, optimise inventory, and scale services to meet growing demand. This synergy allows MedPal app users to access telemedicine and telehealth services, optimising speed and affordability, making primary care available instantly and affordably, facilitating better health outcomes than conventional processes where users frequently encounter accessibility challenges such as delays and/or high costs.
Jason Drummond, CEO of MedPal AI commented:
"This distribution centre represents a milestone in our mission to democratise healthcare. By combining our Medpal AI triage with robotic innovation, we are creating a 24/7 ecosystem that makes primary care accessible and affordable, while always prioritising patient safety through human expertise and oversight."
About MedPal AI
MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.
The addition of an AI-driven consumer platform with automated pharmacy operations to deliver timely, affordable access to medicines and telehealth pathways across the UK is highly complementary to the MedPal app and in line with the Company's stated strategy to explore opportunities to expand into telehealth.
MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.
View the link to watch an interview with CEO Jason Drummond giving more information on the launch of the Centre
https://editor.voxmarkets.co.uk/cms/article/68f7bedd066d459c83ca94bb
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company take responsibility for the contents of this announcement.
Enquiries:
MedPal AI plc via Square1 Consulting
Jason Drummond, Chief Executive Officer
Cairn Financial Advisers LLP +44 20 7213 0880
Louise O'Driscoll/Jo Turner
Clear Capital Markets Limited +44 20 3869 6080
Bob Roberts/ Nick Josh
Square1 Consulting +44 20 7929 5599
David Bick +44 7831 381201
Forward Looking Statements
This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
.png)
Fill out the short form below to get instant access to this free report revealing our Top 10 stock picks for November.
Nothing in the above article should be considered investment advice.
Small Cap or Aquis listed companies can be highly illiquid making them difficult to sell at the quoted price, and in some cases, it may be difficult to sell them at any price. Small Cap or Aquis listed companies can have a large bid / offer spread which means there could be a large difference between the buying and selling price. Companies listed on the Aquis market can be highly volatile and are considered high risk speculative investments. The value of your investment can go down as well as up, your Capital is at risk you may not get back the amount invested. Please ensure that you fully understand the risks involved. If in any doubt, please seek independent financial advice. This document is published by Clear Capital Markets and does not constitute a solicitation or personal recommendation for the purchase or sale of investment. The investments referred to may not be suitable for all investors. Any data or views given should not be construed as investment advice. Every effort is made to ensure the accuracy of the information, but no assurance or warranties are given.
Clear Capital Markets Corporate Broking acts as a Corporate Broker to MedPal PLC and holds warrants and shares in the company. Employees and/or directors of Clear Capital Markets may deal in shares of MedPal PLC for their own personal accounts. These scenarios may give rise to a conflict of interest where Clear Capital Markets also provides clients with an advisory service for transactions involving MedPal PLC. The firm has established Conflicts of Interest (“COI”) and Personal Account Dealing (“PAD”) policies to mitigate the risk of a conflict causing damage to the interests of its clients. The measures taken include (i) enforcing minimum holding or ‘lock-in’ periods; and (ii) requiring internal review and approval from the compliance department for employees or directors entering into personal transactions involving MedPal PLC. The COI and PAD policies are available upon request. Before Clear Capital Markets proceeds with a placing, a number of factors are considered including: liquidity of stock, company diversification, market capitalisation and potential news flow. Only once minimum criteria are satisfied would we elect to proceed. Any remuneration payable to Clear Capital Markets has no bearing on whether it proceeds with a placing. These administrative controls mitigate the risk of a conflict causing damage to the interest of a client, but the inherent risks of this business model cannot be eliminated. Accordingly, Clear Capital Markets is required to disclose this conflict to help clients to assess the service that they are being offered in light of Clear Capital’s own interests, and to decide on the extent (if at all) to which they will rely on, or proceed with, the service.
We will reach out for a quick introductory fact find to see how we can best serve your specific needs and arrange a convenient time for a consultation with a member of the appropriate specialist team.
An Advisory Broker will contact you for a deeper fact find and share information on how we can best enhance your portfolio.
We will conduct a full RCP in accordance with FCA regulations to ensure that your appropriate risk profile is set. You will then have access to an extensive suite of investments, supported by your dedicated Advisory Broker.
